Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8709005 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL8836623 | 0.79 | KDM4E (0.45) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL27703610 | 0.77 | SLC6A2 (0.48) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL8836467 | 0.75 | TERT (0.45) | SLC6A2MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL8836020 | 0.74 | SLC6A2 (0.46) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL3632244 | 0.74 | SLC6A2 (0.56) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| Hydrochloric Acid SCHEMBL8835778 | 0.73 | SLC6A2 (0.44) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL11452265 | 0.70 | SLC6A2 (0.51) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL8836040 | 0.70 | SLC6A2 (0.51) | SLC6A2SLC6A4MEN1KMT2AHDAC1 | |
| SCHEMBL8612793 | 0.69 | CNR2 (0.56) | MEN1KMT2AKDM4ECNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678135-B1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7112682-B2 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1678135-A1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | Aventis Pharmaceuticals, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035496-A1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AADAT, KMO, KYNU | SLC6A2 675/4885SLC6A4 290/4885MEN1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.